hydroxyurea has been researched along with Neutropenia in 25 studies
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)." | 7.81 | Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015) |
| "The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)." | 3.81 | Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015) |
| " In this study, we utilized these synergistic effects of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]), hydroxyurea, and low-dose cytosine arabinoside to treat elderly patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)." | 3.73 | GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. ( Chan, GW; Miller, KB; Winer, ES, 2005) |
| " Neutropenia, caused by the application of hydroxyurea, however, inhibit the pulmonary clearance markedly and reduced the severity of simultaneously induced pneumonias considerably." | 3.69 | [Experimental affecting of pulmonary clearance of Pasteurella multocida induced pneumonia in swine]. ( Köhler, H; Müller, G, 1997) |
| "An animal model of leukotriene B4- (LTB4) induced neutropenia has been developed to evaluate LTB4 receptor antagonists in vivo." | 3.68 | LTB4-induced transient neutropenia in the rat: a model for evaluating efficacy and bioavailability of LTB4 receptor antagonists. ( Colombo, C; DiPasquale, G; Fryer, LR; Greenspan, PD; Haston, W; Healy, C; Kotyuk, B; Pastor, G; Pellas, TC; Raychaudhuri, A, 1993) |
| "Twenty-six Holstein calves were treated with hydroxyurea in order to induce neutropenia." | 3.67 | Neutrophil depletion of calves with hydroxyurea: methods and clinical and pathologic effects. ( Derksen, FJ; Ingersoll, R; Malark, J; Robinson, NE; Slocombe, RF, 1986) |
| "Despite the widespread usage of hydroxyurea in the treatment of both malignant and nonmalignant diseases and a recent expansion in the recognition of its potential therapeutic applications, there have been few detailed studies of hydroxyurea's pharmacokinetic (PK) behavior and oral bioavailability." | 2.69 | A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ( Eckardt, JR; Hilsenbeck, SG; Hodges, S; Kuhn, JG; Rinaldi, DA; Rodriguez, GI; Rowinsky, EK; Thurman, A; Von Hoff, DD; Weiss, GR, 1998) |
| " The concentration of hydroxyurea in plasma decayed monoexponentially with a mean +/- SE half-life of 3." | 2.68 | Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ( Ahn, CW; Akman, SA; Carroll, M; Chow, W; Coluzzi, P; Doroshow, JH; Hamasaki, V; Leong, LA; Margolin, KA; Morgan, RJ; Newman, EM; Raschko, JW; Shibata, S; Somlo, G; Tetef, M; Yen, Y, 1997) |
| "Changes in blood biochemistry, resembling adrenocortical hyperfunction, induced by oral administration with hydroxyurea (HYD) at a dosage of 800 mg/Kg/d for 5 days (K+ and total protein decrease, total cholesterol increase) are not modified or enhanced (total protein) by adrenalectomy." | 1.27 | Possible adrenal involvement in hydroxyurea toxicity defense mechanisms. ( Macrae, S; Nunziata, A; Preziosi, P; Ragazzoni, E; Vacca, M, 1985) |
| "All rabbits died of respiratory failure with pulmonary edema, and although chemotherapy decreased the number of neutrophils in the lungs by greater than 90%, it did not influence survival time or extravascular lung water content." | 1.27 | Oxygen-induced lung microvascular injury in neutropenic rabbits and lambs. ( Bland, RD; Hazinski, TA; Raj, JU, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (24.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Beshlawy, A | 1 |
| El-Ghamrawy, M | 1 |
| EL-Ela, MA | 1 |
| Said, F | 1 |
| Adolf, S | 1 |
| Abdel-Razek, AR | 1 |
| Magdy, RI | 1 |
| Abdel-Salam, A | 1 |
| Chu, MM | 1 |
| Ma, Y | 1 |
| Tse, KY | 1 |
| Chan, KK | 1 |
| Ngan, HY | 1 |
| Harousseau, JL | 1 |
| Martinelli, G | 1 |
| Jedrzejczak, WW | 1 |
| Brandwein, JM | 1 |
| Bordessoule, D | 1 |
| Masszi, T | 1 |
| Ossenkoppele, GJ | 1 |
| Alexeeva, JA | 1 |
| Beutel, G | 1 |
| Maertens, J | 1 |
| Vidriales, MB | 1 |
| Dombret, H | 1 |
| Thomas, X | 1 |
| Burnett, AK | 1 |
| Robak, T | 1 |
| Khuageva, NK | 1 |
| Golenkov, AK | 1 |
| Tothova, E | 1 |
| Mollgard, L | 1 |
| Park, YC | 1 |
| Bessems, A | 1 |
| De Porre, P | 1 |
| Howes, AJ | 1 |
| Chen, TH | 1 |
| Chang, JG | 1 |
| Yang, YH | 1 |
| Mai, HH | 1 |
| Liang, WC | 1 |
| Wu, YC | 1 |
| Wang, HY | 1 |
| Huang, YB | 1 |
| Wu, SM | 1 |
| Chen, YC | 1 |
| Yang, SN | 1 |
| Jong, YJ | 1 |
| Weatherall, DJ | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Herndon, JE | 1 |
| Coan, A | 1 |
| Gururangan, S | 1 |
| Peters, KB | 1 |
| McLendon, R | 1 |
| Sathornsumetee, S | 1 |
| Rich, JN | 1 |
| Lipp, ES | 1 |
| Janney, D | 1 |
| Friedman, HS | 1 |
| Levenga, H | 1 |
| Donnelly, P | 1 |
| Blijlevens, N | 1 |
| Verweij, P | 1 |
| Shirango, H | 1 |
| de Pauw, B | 1 |
| Winer, ES | 1 |
| Miller, KB | 1 |
| Chan, GW | 1 |
| Dresch, C | 1 |
| El Kebir, N | 1 |
| Metral, J | 1 |
| Karsdorf, A | 1 |
| Vokes, EE | 1 |
| Haraf, DJ | 1 |
| Drinkard, LC | 1 |
| Hoffman, PC | 1 |
| Ferguson, MK | 1 |
| Vogelzang, NJ | 1 |
| Watson, S | 1 |
| Lane, NJ | 1 |
| Golomb, HM | 1 |
| Pellas, TC | 1 |
| Colombo, C | 1 |
| Fryer, LR | 1 |
| Pastor, G | 1 |
| Haston, W | 1 |
| Raychaudhuri, A | 1 |
| Kotyuk, B | 1 |
| Greenspan, PD | 1 |
| Healy, C | 1 |
| DiPasquale, G | 1 |
| Newman, EM | 1 |
| Carroll, M | 1 |
| Akman, SA | 1 |
| Chow, W | 1 |
| Coluzzi, P | 1 |
| Hamasaki, V | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Raschko, JW | 1 |
| Shibata, S | 1 |
| Somlo, G | 1 |
| Tetef, M | 1 |
| Yen, Y | 1 |
| Ahn, CW | 1 |
| Doroshow, JH | 1 |
| Rogers, ZR | 1 |
| Rodriguez, GI | 1 |
| Kuhn, JG | 1 |
| Weiss, GR | 1 |
| Hilsenbeck, SG | 1 |
| Eckardt, JR | 1 |
| Thurman, A | 1 |
| Rinaldi, DA | 1 |
| Hodges, S | 1 |
| Von Hoff, DD | 1 |
| Rowinsky, EK | 1 |
| Gómez, FP | 1 |
| Iglesia, R | 1 |
| Roca, J | 1 |
| Barberà, JA | 1 |
| Chung, KF | 1 |
| Rodriguez-Roisin, R | 1 |
| Müller, G | 1 |
| Köhler, H | 1 |
| Finazzi, G | 1 |
| Barbui, T | 1 |
| Wassmann, B | 1 |
| Klein, SA | 1 |
| Scheuring, U | 1 |
| Pfeifer, H | 1 |
| Martin, H | 1 |
| Gschaidmeier, H | 1 |
| Hoelzer, D | 1 |
| Ottmann, OG | 1 |
| Yoshida, M | 1 |
| Lo, SK | 1 |
| Garcia-Szabo, RR | 1 |
| Malik, AB | 1 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Schutt, AJ | 1 |
| Douglass, HO | 1 |
| Slocombe, RF | 1 |
| Malark, J | 1 |
| Ingersoll, R | 1 |
| Derksen, FJ | 1 |
| Robinson, NE | 1 |
| Preziosi, P | 2 |
| Nunziata, A | 1 |
| Macrae, S | 1 |
| Ragazzoni, E | 1 |
| Vacca, M | 2 |
| De Gori, N | 1 |
| Del Carmine, R | 1 |
| Navarra, PL | 1 |
| Raj, JU | 1 |
| Hazinski, TA | 1 |
| Bland, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or Older (Farnesyl Transferase Inhibition Global Human Trials AML 301 [F.I.G.H.T. AM[NCT00093990] | Phase 3 | 457 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxyurea and Neutropenia
| Article | Year |
|---|---|
Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger?
Topics: Actinomycetales; Actinomycetales Infections; Acyclovir; Antineoplastic Combined Chemotherapy Protoco | 2004 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
[Management of complications in patients with chronic myelogenous leukemia].
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Graft vs Host Disease; Hematop | 2001 |
9 trials available for hydroxyurea and Neutropenia
| Article | Year |
|---|---|
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; | 2009 |
Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy.
Topics: Adolescent; Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; F | 2010 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
Topics: Adult; Antineoplastic Agents; Drug Administration Schedule; Humans; Hydroxyurea; Infusions, Intraven | 1997 |
Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Erythrocyte Indices; Fe | 1997 |
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Half-Life; Humans; | 1998 |
The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma.
Topics: Adult; Airway Resistance; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydroxyur | 1998 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
13 other studies available for hydroxyurea and Neutropenia
| Article | Year |
|---|---|
Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Combined Modality Therapy | 2014 |
Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Female; Gesta | 2015 |
Hydroxycarbamide for sickle-cell anaemia in infancy.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea; Infant; Neutropenia | 2011 |
GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2005 |
Cytosine arabinoside as a suicide agent for human colony forming cells.
Topics: Bone Marrow Cells; Cells, Cultured; Cytarabine; Cytotoxicity, Immunologic; Dose-Response Relationshi | 1983 |
LTB4-induced transient neutropenia in the rat: a model for evaluating efficacy and bioavailability of LTB4 receptor antagonists.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents, Non | 1993 |
[Experimental affecting of pulmonary clearance of Pasteurella multocida induced pneumonia in swine].
Topics: Animals; Carrageenan; Hydroxyurea; Lung; Macrophages; Monocytes; Neutropenia; Pasteurella multocida; | 1997 |
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; C | 2001 |
Leukocyte repletion reverses protective effect of neutropenia in thrombin-induced increase in lung vascular permeability.
Topics: Agranulocytosis; Animals; Capillary Permeability; Hydroxyurea; Leukocyte Count; Leukocytes; Lung; Ly | 1990 |
Neutrophil depletion of calves with hydroxyurea: methods and clinical and pathologic effects.
Topics: Agranulocytosis; Animals; Bone Marrow; Cattle; Cattle Diseases; Hydroxyurea; Male; Neutropenia | 1986 |
Possible adrenal involvement in hydroxyurea toxicity defense mechanisms.
Topics: Adrenalectomy; Animals; Blood Proteins; Cholesterol; Corticosterone; Hydroxyurea; Leukocyte Count; M | 1985 |
Replacement therapy against increased hydroxyurea toxicity in pituitary or adrenal ablated rats.
Topics: Adrenalectomy; Agranulocytosis; Animals; Corticosterone; Cosyntropin; Desoxycorticosterone; Drug The | 1985 |
Oxygen-induced lung microvascular injury in neutropenic rabbits and lambs.
Topics: Agranulocytosis; Animals; Blood Pressure; Capillary Permeability; Cardiac Output; Hydroxyurea; Lung; | 1985 |